These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38567555)

  • 21. Longitudinal Changes in Clinical Features, Management, and Outcomes of Idiopathic Pulmonary Fibrosis. A Nationwide Cohort Study.
    Moon SW; Kim SY; Chung MP; Yoo H; Jeong SH; Kim DS; Song JW; Lee HL; Choi SM; Kim YW; Kim YH; Park CS; Park SW; Park JS; Jegal Y; Lee J; Uh ST; Kim TH; Lee JH; Kim YH; Shin B; Lee HK; Yang SH; Lee H; Kim SH; Lee EJ; Choi HS; Shin H; Park YB; Shin JW; Park MS
    Ann Am Thorac Soc; 2021 May; 18(5):780-787. PubMed ID: 33270528
    [No Abstract]   [Full Text] [Related]  

  • 22. Investigation of clinical predictors of survival in idiopathic pulmonary fibrosis patients: A cohort study in Taiwan.
    Tseng CM; Chen MY; Kao CY; Tao CW
    J Chin Med Assoc; 2022 May; 85(5):578-583. PubMed ID: 35353790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment.
    Biondini D; Cocconcelli E; Bernardinello N; Lorenzoni G; Rigobello C; Lococo S; Castelli G; Baraldo S; Cosio MG; Gregori D; Saetta M; Balestro E; Spagnolo P
    Respir Res; 2021 Apr; 22(1):98. PubMed ID: 33794872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved Prognostic Prediction by Combination of Early Initiation of Polymyxin B Hemoperfusion with Modified Gender-Age-Physiology Index in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.
    Oishi K; Azuma A; Abe S; Murata Y; Sakamoto K; Mimura Y; Asami-Noyama M; Kakugawa T; Hirano T; Matsunaga K
    Blood Purif; 2022; 51(6):485-491. PubMed ID: 34518460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry.
    Salisbury ML; Conoscenti CS; Culver DA; Yow E; Neely ML; Bender S; Hartmann N; Palmer SM; Leonard TB;
    Ann Am Thorac Soc; 2020 Nov; 17(11):1413-1423. PubMed ID: 32574517
    [No Abstract]   [Full Text] [Related]  

  • 26.
    Doubkova M; Kriegova E; Littnerova S; Schneiderova P; Sterclova M; Bartos V; Plackova M; Zurkova M; Bittenglova R; Lostaková V; Siskova L; Lisa P; Suldova H; Doubek M; Psikalova J; Snizek T; Musilova P; Vasakova M
    Ther Adv Respir Dis; 2021; 15():17534666211042529. PubMed ID: 34515605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat.
    Maher TM; Strek ME
    Respir Res; 2019 Sep; 20(1):205. PubMed ID: 31492155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
    Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
    BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis.
    Enomoto N; Naoi H; Aono Y; Katsumata M; Horiike Y; Yasui H; Karayama M; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Inui N; Nakamura Y; Suda T
    Ther Adv Respir Dis; 2020; 14():1753466620935774. PubMed ID: 32600180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis.
    Cilli A; Uzer F; Sevinç C; Coşkun F; Ursavaş A; Öner Ş; Kose F
    Pulm Pharmacol Ther; 2021 Dec; 71():102099. PubMed ID: 34793978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of low-dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): Results from a real-world study.
    Lee EG; Lee TH; Hong Y; Ryoo J; Heo JW; Gil BM; Kang HS; Kwon SS; Kim YH
    PLoS One; 2021; 16(12):e0261684. PubMed ID: 34941933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis.
    Adegunsoye A; Alqalyoobi S; Linderholm A; Bowman WS; Lee CT; Pugashetti JV; Sarma N; Ma SF; Haczku A; Sperling A; Strek ME; Noth I; Oldham JM
    Chest; 2020 Oct; 158(4):1526-1534. PubMed ID: 32450241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Concomitant Medication Burden on Tolerability of Disease-targeted Therapy and Survival in Interstitial Lung Disease.
    Khor YH; Goh NSL; Wong AW; Johannson KA; Marcoux V; Fisher JH; Assayag D; Manganas H; Khalil N; Kolb M; Ryerson CJ;
    Ann Am Thorac Soc; 2022 Jun; 19(6):962-970. PubMed ID: 35007498
    [No Abstract]   [Full Text] [Related]  

  • 35. Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
    Takehara K; Koga Y; Hachisu Y; Utsugi M; Sawada Y; Saito Y; Yoshimi S; Yatomi M; Shin Y; Wakamatsu I; Umetsu K; Kouno S; Nakagawa J; Sunaga N; Maeno T; Hisada T
    Cells; 2022 Jan; 11(1):. PubMed ID: 35011705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Historical eye on IPF: a cohort study redefining the mortality scenario.
    Tomassetti S; Ravaglia C; Piciucchi S; Ryu J; Wells A; Donati L; Dubini A; Klersy C; Luzzi V; Gori L; Rosi E; Lavorini F; Poletti V
    Front Med (Lausanne); 2023; 10():1151922. PubMed ID: 37332746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Idiopathic pulmonary fibrosis prognostic factors - analysis of the Czech registry].
    Doubková M; Uher M; Bartoš V; Šterclová M; Lacina L; Lošťáková V; Binková I; Plačková M; Žurková M; Bittenglová R; Pšikalová J; Šišková L; Lisá P; Petřík F; Polák J; Řihák V; Skřičková J; Vašáková M
    Cas Lek Cesk; 2016; 155(4):22-8. PubMed ID: 27481198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physician characteristics associated with treatment initiation patterns in idiopathic pulmonary fibrosis.
    LaCamera PP; Limb SL; Haselkorn T; Morgenthien EA; Stauffer JL; Wencel ML
    Chron Respir Dis; 2019; 16():1479973119879678. PubMed ID: 31558049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: a propensity score matching analysis.
    Kang J; Han M; Song JW
    Sci Rep; 2020 Sep; 10(1):15620. PubMed ID: 32973215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Racial and ethnic disparities in antifibrotic therapy in idiopathic pulmonary fibrosis.
    Zhao J; Fares J; George G; Maheu A; Loizidis G; Roman J; Kramer D; Li M; Summer R
    Respirology; 2023 Nov; 28(11):1036-1042. PubMed ID: 37534632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.